TREATMENT OF SLEEP APNEA

Two Year Reduction In Sleep Apnea Symptoms and Associated Diabetes Incidence After Weight Loss In Severe Obesity

Ronald R. Grunstein, MD, PhD1,2; Kaj Stenlöf, MD, PhD3; Jan A. Hedner, MD, PhD3;2; Markku Peltonen, PhD4; Kristjan Karason, MD, PhD5; Lars Sjöström, MD, PhD2

Departments of Pulmonary and Sleep Medicine,1 Medicine,2 and Cardiology,3 Sahlgrenska University Hospital, Göteborg, Sweden; 4NHMRC Centre for Respiratory and Sleep Medicine, Woolcock Institute of Medical Research, Royal Prince Alfred Hospital and University of Sydney, Camperdown, Sydney, Australia; 5Diabetes Unit, National Public Health Institute, Helsinki, Finland

Study Objectives: To evaluate the effect of bariatric surgery on sleep apnea symptoms and obesity-associated morbidity in patients with severe obesity.

Design: Prospective study.

Setting: University hospitals and community centers in Sweden.

Intervention: We investigated the influence of weight loss surgery (n=1729) on sleep apnea symptoms and obesity-related morbidity using a conservatively treated group (n=1748) as a control.

Measurements and Results: Baseline BMI in surgical group (42.2±4.4 kg/m2) and control group (40.1±4.6 kg/m2) changed −9.7±5 kg/m2 and 0±3 kg/m2, respectively, at 2-year follow-up. In the surgery group, there was a marked improvement in all obstructive sleep apnea (OSA) symptoms compared with the control group (P <0.001). Persistence of snoring (21.6 vs 65.5%, adjusted OR 0.14, 95% CI 0.10-0.19) and apnea (27.9 vs 71.3%, adjusted OR 0.16, 95% CI 0.10-0.23) were much less in the surgery group compared with controls. Compared with subjects with no observed apnea at follow-up (n=2453), subjects who continued to have or developed observed apnea (n=404) had a higher incidence of diabetes (adjusted OR 2.03, 95% CI 1.19-3.47) and hypertriglyceridemia (adjusted OR 1.86, 95% CI 1.07-3.25) but not hypertension (adjusted OR 1.09, 95% CI 0.65-1.83) or hypercholesterolemia (adjusted OR 0.91, 95% CI 0.53-1.58).

Conclusion: Bariatric surgery results in a marked improvement in sleep apnea symptoms at 2 years. Despite adjustment for weight change and baseline central obesity, subjects reporting loss of OSA symptoms had a lower 2-year incidence of diabetes and hypertriglyceridemia. Improvement in OSA in patients losing weight may provide health benefits in addition to weight loss alone.

Keywords: Sleep, snoring, sleep apnea, obesity, diabetes, bariatric surgery

Citation: Grunstein RR; Stenlöf KS; Hedner JA et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. SLEEP 2007;30(6):703-710.

Disclosure Statement

This was not an industry supported study. Dr. Grunstein has received research support from GlaxoSmithKline, Neurocrine, Sanofi-Aventis, and Cephalon; has participated in a speaking engagement for Roche Pharmaceuticals; and has received travel assistance from Respironics. Drs. Stenlöf, Hedner, Peltonen, Karason, and Sjöström have indicated no financial conflicts of interest.

Submitted for publication June 2006

Accepted for publication March 2007

Address correspondence to: Ron Grunstein, Sleep and Circadian Research Group, Woolcock Institute of Medical Research, E11 Sleep Unit, Royal Prince Alfred Hospital, Camperdown, Sydney 2050, Australia; Tel: +61-2-95158630; Fax: +61-2-95157070; E-mail: rrg@med.usyd.edu.au

SLEEP, Vol. 30, No. 6, 2007
rates among obese people who lose weight by surgical means differ from those in a matched obese reference group.\textsuperscript{13,15} SOS consists of a registry study and an intervention study.\textsuperscript{13} The criteria for inclusion in the intervention study are age between 37 and 60 years, BMI \(\geq 38\) kg/m\(^2\) for women, and BMI \(\geq 34\) kg/m\(^2\) for men. Severe illness, abuse of alcohol or drugs, and previous bariatric surgery were reasons for exclusion, whereas diabetes, hypertension, and previously experienced (not within the last 6 months) myocardial infarction were not.

The study was not randomized since the ethics committees in Sweden did not approve randomization into surgical or control groups. Instead, patients willing to undergo surgical therapy were computer matched to those preferring conventional treatment with respect to sex and 18 other clinical variables. These were age, height, weight, waist and hip circumferences, waist/hip ratio, systolic blood pressure, cholesterol, triglycerides, smoking, diabetes, menopause, and six parameters evaluating psychological status: perceived health, psychasthenia, monotony avoidance, available social interaction, availability of attachment, and stressful life events.

Surgical procedures used for weight reduction included gastric bypass, vertical banded gastroplasty, and gastric banding.\textsuperscript{15} Surgery and follow-up was conducted at 25 different surgical departments in Sweden. Control subjects received routine obesity management offered at 480 primary health care centres located throughout the country. These treatments included dietary advice, physical training, low calorie diets, and behavior modification. No anti-obesity drugs were registered in Sweden during the study period.

**Treatments and Study Groups**

We examined data at baseline and at 2-year follow-up for subjects included in the study prior to September 30, 1998. Table 1 shows the clinical characteristics of the surgery and control groups who completed 2-year follow-up. At baseline, the surgical and control groups were similar with respect to gender and living arrangements. The average interval between registry examination and baseline examination in the intervention study was 9 months. During this initial period between matching and inclusion, the group awaiting surgery gained weight while the control group lost weight, resulting in a difference in body weight. Patients in the surgical group were slightly younger than those in the control group, had a higher prevalence of hypertension and diabetes, and were more frequently smokers.

**Sleep Apnea Questions**

All subjects completed an 8-item sleep questionnaire at baseline and at 2-year follow-up using questions identical to those used in previous cross-sectional and longitudinal surveys in Sweden and validated against polysomnography in a subsample.\textsuperscript{16,17} Subjects were asked if they had a current regular home partner. The survey included the following questions directly related to sleep apnea—two questions utilizing a 5-point scale (never, rarely, sometimes, often, very often), one related to presence of loud and disruptive snoring, and another related to frequent daytime sleepiness. Subjects reporting “often” or “very often” were con-
considered to be frequent snorers or to have frequent daytime sleepiness, respectively. In addition to these questions, subjects were asked whether a partner or another family member had observed frequent pauses in breathing during sleep (yes/no).^1,14

**Measurements**

Anthropomorphic measurements (body weight, height, neck, waist and hip circumference) were measured as previously described. Systolic and diastolic (phase V) blood pressures were measured in the right arm using a mercury sphygmomanometer after 15 minutes of supine rest (single reading). Cuff width and upper arm circumference were recorded in each individual case. The blood pressures were adjusted for any incongruities in these measurements before analysis. ^18

**Laboratory Data**

Blood samples were obtained in the morning after 10-12 hours of fasting. Serum insulin was measured radioimmunochemically. Blood glucose and the remaining serum tests were analysed by enzymatic techniques.

**Criteria for Health and Disease**

The diagnosis of diabetes was based on the presence of fasting glucose ≥7.8 mmol/L and/or self-reported use of anti-diabetic medication. Cut-off values used for definitions of hypertriglyceridemia and hypercholesterolemia were serum triglycerides ≥ 2.8 mmol/L and total serum cholesterol ≥5.2 mmol/L, respectively. The diagnosis of hypertension required a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg and/or medication prescribed specifically against hypertension. The incidence calculations are based on the diagnoses of developed diabetes, hypertension, hypertriglyceridemia, or hypercholesterolemia among individuals who were not affected by these conditions at the start of the intervention. Persistence of disease was calculated based on continuation of diagnoses at 2-year follow-up. For the purpose of analysing data on incidence or persistence of comorbidity, the presence of sleep apnea was determined by a positive response to the question regarding frequent observed breathing pauses during sleep and is denoted as observed apnea in the text. Analysis using observed apneas plus snoring and sleepiness resulted in a restricted population not suitable for multivariate analyses.

**Statistical Methods**

Fisher’s exact test was used to compare incidence and persistence proportions of sleep apnea symptoms between the 2 treatment groups. Further, to control for baseline differences between the 2 treatment groups, a logistic regression model was used, adjusting for sex, age, BMI, smoking, diabetes, alcohol, and neck circumference. We report odds ratios (OR) with 95% confidence intervals (CI). The control group was always used as the reference group. Data were analyzed according to intention to treat, so that subjects in the control group who may have had surgery outside of the study are included in the control group.

After pooling the 2 treatment groups, the incidence and persistence proportions were examined in relation to degree of change in body weight. Changes in body weight were calculated as percent of the initial value and grouped in quartiles. Logistic regression models adjusting for baseline differences were used to compared the 4 weight change groups. The quartile with least weight change was used as the reference, and odds ratios and 95% CIs are reported.

Similarly logistic regression models were used to study incidence and persistence of diabetes, hypertension, and hyperlipidemia in relation to sleep apnea status. All the analyses were performed using the Stata statistics package (Stata Statistical Software: Release 7.0, Stata Corporation, College Station, TX, USA).

**RESULTS**

Baseline characteristics of subjects completing the 2-year follow-up are shown in Table 1. Among the 1592 surgically treated patients available at 2 years, 1143 (71.8%) underwent vertical banded gastroplasty (VBG), 325 (20.4%) gastric banding, and 124 (7.8%) gastric bypass. These operations were performed at 25 surgical departments located throughout Sweden. Calculations performed in February 2000 showed a perioperative mortality rate of 0.21%, and the incidence of other surgical complications (bleeding, embolus and/or thrombosis, wound complications, deep infections, pulmonary, and other complications) was 13%.

There was substantial weight reduction in the surgery group at 2 years. The mean weight loss in surgically treated patients was 27.8 kg, corresponding to 23% of baseline weight. Mean BMI decreased from 42.2 to 32.5 kg/m^2 compared with baseline weight. The average weight in the control group remained essentially unchanged. Greater than 10% weight loss was achieved by approximately 50% of the entire SOS study group. Average relative weight loss in the surgery group was 21.9% and 23.3% in men and women, respectively (P = 0.015). This could in part be explained by different inclusion criteria for men and women in the study.

**Weight Change and Sleep Apnea Symptoms**

To evaluate appearance of new sleep apnea-related symptoms, we analysed data in subjects without symptoms at baseline. The development of new symptoms of apneas and snoring was approximately 4 to 5 times lower in the surgery group than the control group (Table 2). The incidence of sleepiness was also lower in the surgery group (Table 2). Of the subjects in the surgery group with frequent complaints at baseline, only 20%-30% had persisting symptoms at follow-up (Table 2). In contrast, approximately 50%-70% of control subjects reported persistent symptoms.

The improvement in symptoms of apneas and daytime sleepiness was similar in surgically treated men and women. In contrast, reduction in the incidence of snoring was larger in surgically treated women as compared to men. The ORs for comparison of treatment groups were 0.36 and 0.13 in men and women, respectively (P = 0.024 for sex-treatment interaction).

To investigate the relationship between degree of weight loss and change in sleep apnea symptoms, we stratified the entire study sample (surgery and control groups) into quartiles, according to change in weight from baseline. There was a dose-response effect of weight loss on sleep apnea symptoms (Figures
and 2). Subjects in the quartile with the greatest weight loss were 2-13 times less likely to report the development of new sleep apnea symptoms (Figure 1) and 2.5-7 times less likely to report continuing sleep apnea symptoms than subjects in the quartile with the least weight change (Figure 2). Even in the second quartile, corresponding to a weight reduction of 0.0% to 11.0% of baseline body weight, the odds ratio for a report of frequent apneas, snoring, and daytime sleepiness was reduced by approximately 50%.

In general, the effect of weight loss on symptoms of apneas, snoring, and daytime sleepiness was similar in men and women. For snoring and daytime sleepiness, however, there was a statistically significant interaction between sex and weight loss, so that men with greatest weight loss had relatively larger improvement in these symptoms compared with women with greatest weight loss (sex-weight loss interaction, P = 0.003 for snoring, P = 0.029 for daytime sleepiness).

**DISCUSSION**

This study has demonstrated that symptoms of sleep apnea such as snoring, breathing pauses during sleep, and sleepiness are markedly improved following surgical weight loss in a dose-dependent fashion. These findings have important implications for the management of sleep disordered breathing in patients with severe obesity, supporting an important therapeutic role for bar-

---

**Table 2**—Sleep Apnea Symptoms in Surgery and Control Groups

<table>
<thead>
<tr>
<th></th>
<th>Surgery</th>
<th>Control</th>
<th>P-value</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>1592</td>
<td>1431</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freq. apneas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline, %</td>
<td>24.0</td>
<td>21.8</td>
<td>0.149</td>
<td></td>
</tr>
<tr>
<td>Follow-up, %</td>
<td>8.3</td>
<td>20.8</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Incidence, %</td>
<td>2.3</td>
<td>6.7</td>
<td>&lt;0.001</td>
<td>0.28 (0.16 to 0.49)</td>
</tr>
<tr>
<td>Persistence, %</td>
<td>27.9</td>
<td>71.3</td>
<td>&lt;0.001</td>
<td>0.16 (0.10 to 0.23)</td>
</tr>
<tr>
<td>Freq. snoring</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline, %</td>
<td>44.5</td>
<td>35.6</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Follow-up, %</td>
<td>10.8</td>
<td>29.8</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Incidence, %</td>
<td>2.1</td>
<td>10.0</td>
<td>&lt;0.001</td>
<td>0.18 (0.10 to 0.32)</td>
</tr>
<tr>
<td>Persistence, %</td>
<td>21.6</td>
<td>65.5</td>
<td>&lt;0.001</td>
<td>0.14 (0.10 to 0.19)</td>
</tr>
<tr>
<td>Freq. daytime sleepiness</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline, %</td>
<td>25.8</td>
<td>20.4</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Follow-up, %</td>
<td>12.7</td>
<td>17.8</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Incidence, %</td>
<td>5.9</td>
<td>8.4</td>
<td>0.018</td>
<td>0.66 (0.45 to 0.96)</td>
</tr>
<tr>
<td>Persistence, %</td>
<td>32.6</td>
<td>54.6</td>
<td>&lt;0.001</td>
<td>0.44 (0.30 to 0.63)</td>
</tr>
</tbody>
</table>

**Incidences:** proportion of subjects with symptoms at 2-year among those without reported symptoms at baseline

**Persistences:** proportion of subjects with symptoms at 2-year among those with reported symptoms at baseline

Proportions are unadjusted values. P-value: Fischer’s exact test, unadjusted

OR (95% CI): odds-ratio (95% confidence interval), adjusted for age, sex, BMI, smoking, diabetes, alcohol, and neck circumference at baseline

---

---

---

---

---

---

---
These data also add to previous reports from the SOS cohort demonstrating that a 2-year weight loss leads to a dramatic reduction in obesity-related comorbidity such as diabetes, hypertension, and hyperlipidemia. Moreover, the observation that there was a doubling of the odds ratio for incidence of either diabetes or hypertriglyceridemia with development or maintenance of observed apnea suggests a contributory role for OSA in some obesity related morbidity. These metabolic findings persisted even after adjustment for weight change and a range of other confounding variables, including neck size, as a marker of central obesity. In contrast, observed apneas in this cohort were not associated with the development of hypertension or hypercholesterolemia during the follow-up period.

The SOS study offers a unique opportunity to investigate OSA symptom change prospectively in a large cohort of obese subjects. It provides the first controlled study addressing the impact of weight loss on these symptoms and associated morbidity. There are several key observations in this analysis of 2-year follow-up data. Firstly, sustained weight loss leads to a marked reduction in symptoms of sleep apnea. Secondly, symptom reduction was proportional to the degree of weight loss. Subjects in the quartile with the greatest weight loss were 2.5-7 times less likely to report continuing sleep apnea symptoms than subjects in the quartile with the least weight change. Odds ratios and confidence intervals expressed relative to the quartile with the least weight loss (OR 1.0).

**Diabetes:** ≥6.1 mmol/L/self-reported use of antidiabetic medication

**Hypertension:** ≥140/90 mmHg/self-reported use of antihypertensive medication

**Hypertriglyceridemia:** triglycerides ≥2.8 mmol/L

**Hypercholesterolemia:** total cholesterol ≥5.2 mmol/L

Proportions are unadjusted values.

OR (95% CI): odds-ratio (95% confidence interval), adjusted for age, sex, BMI, waist circumference, relative weight change, smoking, diabetes, alcohol, and neck circumference at baseline.
reported frequent apneas, 9.6% reported frequent snoring, and 24.8% reported frequent daytime sleepiness.

Symptoms suggestive of sleep apnea were extremely common in the SOS cohort at baseline. Frequent snoring was reported in 44.5% of subjects who subsequently underwent bariatric surgery. In these subjects at 2-year follow-up, 10.8% still reported frequent snoring. This level of snoring prevalence is similar to that (14.7%) found in a previously published random sample of 2,668 Swedish non-obese males (mean BMI 27) with an almost identical mean age using identical survey questions. Therefore, the surgical intervention in the SOS study had a major impact on snoring prevalence reducing the frequency of this symptom to that found randomly in the population. In fact, there appeared to be an almost linear association between the degree of weight loss in the whole SOS cohort and reduction in symptoms of sleep disordered breathing.

Weight loss is frequently mentioned as a treatment alternative for OSA. Small and uncontrolled studies of bariatric surgery have reported a dramatic reduction of OSA in the short term, though the amount of weight loss achieved by surgical intervention may not be correlated with improvement in OSA. Long-term controlled studies examining the effect of weight loss on OSA or OSA-related symptoms have not previously been performed. Observations in the Wisconsin Sleep Cohort have demonstrated that subjects who lose weight reduce the severity of sleep disordered breathing. However, this study involved a population with a mean BMI of 29 at baseline, and the median number of OSA events was low in contrast to our population that was more obese and therefore more likely to have worse OSA. Our data supports a dose-response effect for weight loss on sleep apnea symptoms and further shows that the impact of weight loss on OSA is sustained long-term.

Weight loss may reduce OSA severity by a number of mechanisms. Fat deposition adjacent to the upper airway promotes mass loading and obstruction of the upper airway during sleep and is reduced by weight loss. In addition, abdominal obesity reduces lung volumes and may, by means of altered air flow dynamics, mechanically reduce pharyngeal cross-sectional area, and increase pharyngeal resistance. Weight loss leads to an increase in lung volume and reduction in upper airway collapsibility.

We also observed, after adjustment for weight loss, fat distribution, and other variables, that the incidence of diabetes was more than doubled in subjects with newly developed or continuing observed apnea. A number of studies suggest that there is biological plausibility for the role of sleep apnea in the development of obesity-associated comorbidities. An obesity-independent association between OSA and increased insulin levels has previously been observed in the SOS cohort and in other cross-sectional studies. Some studies suggest an improvement in insulin sensitivity with CPAP treatment, although this observation was more pronounced in non-obese patients. The 2-year weight loss adjusted incidence of diabetes in the present study was more than 3 times higher in subjects who developed or maintained observed apnea than those who did not. Similar findings were observed for hypertriglyceridemia. The increased likelihood of comorbid diabetes and hypertriglyceridemia in these patients may be explained by a number of mechanisms. Recent studies in patients with OSA have found evidence of endothelial dysfunction, increased concentrations of leptin, tumour necrosis factor-alpha and free fatty acids, and elevated muscle sympathetic nerve activity. All these abnormalities have been identified as contributors to the pathogenesis of diabetes in severe obesity. It is possible that the diabetes in these SOS study subjects may be influenced by coexistent sleep disordered breathing. This situation may be different in less obese subjects, in whom there does not seem to be an obesity-independent effect of OSA in the development of diabetes.

Previous work in the general population has observed that the likelihood of newly developed hypertension appears to be nearly three times higher in subjects with sleep apnea independent of other known hypertension associated risk factors, including central obesity. Treatment of sleep apnea with CPAP has also been associated with a fall in blood pressure. However in this study, in contrast to the finding with diabetes, hypertension incidence or prevalence over the 2-year period (persistence) was unaffected by change in observed apnea. It is possible that hypertension in the severely obese with OSA may involve mechanisms different from those occurring in the general OSA population or that elimination of sleep disordered breathing following weight reduction may be less complete than that generally seen after CPAP treatment of sleep apnea. Moreover, others have recently questioned the independent impact of sleep apnea on hypertension and the efficacy of CPAP in reducing blood pressure.

The strengths of this study include the large size of the cohort, the availability of a control group for surgical intervention, and the use of identical survey instruments and objective testing at 2-year follow-up. One obvious limitation of such a study is the use of survey questions as indices of sleep disordered breathing instead of full polysomnography. Polysomnography was not readily available when the SOS study was conceived in the mid 1980s; instead, survey questions that had been validated against polysomnography in a subgroup were utilized. We used frequent breathing pauses to define sleep apnea for the purposes of investigating OSA influences of obesity-associated morbidity. Although using such a symptom will produce some misclassification relative to polysomnography, it is a specific symptom, and those reporting frequent breathing pauses during sleep are likely to have OSA.

Single blood pressure readings were used as is common in large scale studies of this type, but it is possible that this may lead to misclassification of hypertension compared with serial readings, such as 24-hour blood pressure. Another limitation is that the subjects were not randomised to surgical or control groups, as this was refused by ethics committees at the time the study was initiated. Therefore SOS subjects self-selected therapy, and there may be unrecognised biases with potential effects on measured outcomes. In addition, the BMI of the SOS subjects was at the higher end of weight ranges seen in sleep clinics, and these data may not be able to be generalized to overweight or less obese individuals.

The effectiveness of intentional weight loss in reducing symptoms of sleep disordered breathing has important implications for management of sleep apnea in the obese patient. Nasal CPAP has high efficacy in OSA, but effectiveness is limited. Recent data suggest that less than 30% of patients in Sweden prescribed CPAP comply adequately with this treatment at 1-year follow-up. Patients with obesity also respond poorly to mandibular advancement splints and upper airway surgery. Therefore sustained weight loss has advantages in the overall management of OSA in addition to therapeutic benefits for other morbidity in obesity. For patients with milder degrees of obesity, nonsurgical weight loss strategies...

SLEEP, Vol. 30, No. 6, 2007
may also have a role in the management of OSA, though this will need to be verified by randomized controlled trials (RCT) for the endpoint of OSA. Emerging data from open “proof of concept” studies suggest the potential of this approach. For more severe obesity, bariatric surgery in the SOS study had low morbidity and mortality13 with newer, simpler surgical techniques becoming available.40 When data from randomized studies demonstrating longer term benefits in mortality and morbidity become available, weight loss surgery should be considered as an important treatment alternative in patients with severe obesity and sleep apnea.

ACKNOWLEDGMENTS

The Swedish Obese Subjects (SOS) study is supported by the Swedish Medical Research Council (Grant 19X-05239), Hoffman-La Roche, and the Volvo Research Foundation. Ronald Grunstein was supported by an NHMRC of Australia Practitioner Fellowship.

The SOS Study involves the assistance of 380 primary health care centres in Sweden. Members of the SOS Steering and Safety Committee are B. Larsson, S. Lindstedt, L. Lissner, L. Olbe, M. Sullivan, L. Sjöström (chairman), Sahlsgrensa Hospital, Gothenburg, Sweden; C. Bengtsson, Institute of Primary Care, Gothenburg, Sweden; I. Näslund, Örebro Hospital, Örebro, Sweden; S. Dahlgren, Umeå Hospital, Umeå, Sweden; E. Jonsson, Karolinska Hospital, Stockholm; L. Backman, Danderyd’s Hospital, Stockholm, Sweden; H. Wedel, Nordic Health University, Gothenburg, Sweden; C. Bouchard, Laval University, Quebec. We would also thank to Dr. David Wang for assistance in preparation of this manuscript.

REFERENCES


18. Bouchard, Laval University, Quebec. We would also thank to Dr. David Wang for assistance in preparation of this manuscript.
Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients Eur Resp J (in press).


